The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Consensus Guideline for Advanced Pancreatic Neuroendocrine Tumor

진행성 췌장 신경내분비 종양에서의 일치된 치료 지침

  • Chang, Heung-Moon (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine)
  • 장흥문 (울산대학교 의과대학 서울아산병원 종양내과)
  • Published : 2011.04.01
⟨ Previous Next ⟩

Abstract

The goals of medical treatment for advanced pancreatic neuroendocrine tumor (PNET) are to control hormone-related symptoms and to prolong overall survival. Somatostatin analogues have been used for decreasing the secretion of peptides and relieving symptoms. Recent studies showed that these agents also have an anti-tumor effect and could prolong the survival of patients with advanced PNET. For well-differentiated PNET, streptozocin-based combination chemotherapy has been used for a long time and recent several studies showed survival benefit of targeted agents including angiogenesis inhibitor and mTOR inhibitor. For poorly-differentiated tumors, the number of clinical studies is very limited and the combination of etoposide and cisplatin is widely used. Based on the recent progress in the understanding of tumor biology, newer targeted agents are tested and some of these agents showed promising activity.

Keywords

References

  1. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;303:1189-1194. https://doi.org/10.1056/NEJM198011203032101
  2. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-523. https://doi.org/10.1056/NEJM199202203260804
  3. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999;86:944-948. https://doi.org/10.1002/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P
  4. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-1355. https://doi.org/10.1038/sj.bjc.6690325
  5. Fjallskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101-1107. https://doi.org/10.1002/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V
  6. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232. https://doi.org/10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I
  7. Kulke MH, Stuart K, Earle CC, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. Proc Am Soc Clin Oncol 2006;24:a4044. https://doi.org/10.1200/JCO.2006.06.9823
  8. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-406. https://doi.org/10.1200/JCO.2005.03.6046
  9. Kulke M, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-3410. https://doi.org/10.1200/JCO.2007.15.9020
  10. Niccoli P, Raoul J, Bang Y, et al. Raymond. Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). Proc Am Soc Clin Oncol 2010;28:a4000. https://doi.org/10.1200/jco.2010.28.15_suppl.4000
  11. Hobday TJ, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. Proc Am Soc Clin Oncol 2007;25(18 Suppl):a4504. https://doi.org/10.1200/JCO.2007.12.3901
  12. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-4318. https://doi.org/10.1200/JCO.2008.16.7858
  13. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4563. https://doi.org/10.1200/JCO.2009.22.8510
  14. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110-122. https://doi.org/10.1053/snuc/2002.31025
  15. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111- pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002;32:123-132. https://doi.org/10.1053/snuc.2002.31769
  16. Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003;44:1-6.
  17. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90) Y-DOTATOC. J Nucl Med 2002;43:610-616.
  18. Valkema R, Pauwels S, Kvols LK, et al. Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with [90Y-DOTA0,Tyr3]-octreotide in patients with somatostatin receptor positive tumours. Eur J Nucl Med Mol Imaging 2003;30(Suppl 2):a394.
  19. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-2130. https://doi.org/10.1200/JCO.2007.15.2553
  20. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl): S62-S66.